Tackling chronic migraine: current perspectives

Francisco Javier Carod-Artal
Neurology Department, Raigmore Hospital, Inverness, UK; Universitat Internacional de Catalunya, Barcelona, Spain

Abstract: In the last decade, several diagnostic criteria and definitions have been proposed for chronic migraine (CM). The third edition of the International Classification of Headache Disorders–3 beta, published in 2013, has revised CM diagnostic criteria. CM is defined as "headache occurring on 15 or more days per month for more than 3 months, which has the features of migraine headache on at least 8 days per month." Patients who meet the criteria for CM and for medication-overuse headache should be given both diagnoses. Worldwide, CM prevalence ranges 1%–3%, and its incidence has been estimated to be 2.5% per year. CM is associated with disability and poor quality of life. Modifiable risk factors include (among others): migraine progression (defined as an increase in frequency and severity of migraine attacks); medication and caffeine overuse; obesity; stressful life events; and snoring. CM patients have a significantly higher frequency of some comorbid conditions, including chronic pain, psychiatric disorders, respiratory illness, and some vascular risk factors. Management includes identification and control of comorbidities and risk factors that predispose to CM; treatment and prevention for medication overuse; early treatment for migraine attacks; and an adequate preventive therapy for CM. Several randomized controlled clinical trials have shown the efficacy of topiramate, amitriptyline, onabotulinumtoxinA, and cognitive-behavioral therapy in CM.

Keywords: chronic daily headache, chronic migraine, epidemiology, medication overuse headache, risk factors, treatment

Introduction
Chronic daily headache comprises a group of heterogeneous primary headache disorders with a minimum duration of 4 hours per day and have occurred 15 or more days per month during the last 3 months. The third edition of the International Classification of Headache Disorders (ICHD)–3 beta, published in 2013, has comprehensively defined several primary chronic headache disorders, such as chronic migraine (CM), chronic tension-type headache, new daily persistent headache, and chronic hemicrania continua (Table 1). In this article, the updated diagnostic criteria, risk factors, and treatment for CM will be reviewed.

From the historical point of view, the concept, classification, and nomenclature of CM have evolved in the literature. CM was first defined in the second edition of the ICHD in 2004, as a complication of migraine. Diagnostic criteria required the presence of migraine without aura on 15 or more days per month during the last 3 months in the absence of medication overuse. This definition was judged to be very restrictive. For this reason, it was updated in the 2006 revised criteria. The ICHD–II revised criteria for CM required the patient to have: headache on more than 15 days...
per month for longer than 3 months; migraine on at least eight of these monthly headache days; and no medication overuse. The updated ICHD–3 beta diagnostic criteria are summarized in Table 2. Now, overuse medication is not considered exclusion criteria for CM.

Some authors think that the definition of CM is still unsatisfactory. The term “transformed migraine” was proposed to indicate a type of migraine that clinically has changed, worsened, or become more complicated over time. These authors proposed to distinguish between CM (merely an increase in the number of headache days that maintains most clinical characteristics typical of migraine) from transformed migraine. Transformed migraine would indicate a more severe form; the headache would not present the typical clinical symptoms of migraine, and it would be more difficult to treat than CM.

Although CM is the most common disorder seen in tertiary headache care, the knowledge about this chronic entity may be low, and many practitioners may not be aware of this. The proportion of CM patients that are diagnosed with the disorder may be as low as 25%, and many of them may get a previous diagnosis of chronic sinusopathy, cervicogenic headache, or depression—among others.

### Epidemiology

#### Prevalence and incidence studies

Migraine is a chronic disorder with episodic relapses as other conditions such as angina and epilepsy. Worldwide, prevalence of migraine has been estimated at 14.7%. Migraine was ranked as the third most common disease in the Global Burden of Disease Survey 2010 by the Institute for Health Metrics and Evaluation (Seattle, WA, USA), ranking seventh among specific cause of disability.

In the last few years, several epidemiological studies have analyzed the prevalence and incidence of CM. Data has suffered the bias from the application of different diagnostic criteria and definitions across studies. In addition, heterogeneous interpretation of medication overuse headache (MOH) occurred in some studies. Worldwide, the prevalence of chronic daily headache was estimated to range from 3%–5%, and CM prevalence from 1%–3%.

The population-based German Headache Consortium Study evaluated approximately 10,000 people aged 18–65 years and reported prevalence for chronic headache, CM, and chronic tension-headache was 2.6%, 1.1%, and 0.5%, respectively. The American Migraine Prevalence and Prevention Study (AMPP), a US national longitudinal survey of severe headache, found a CM prevalence of 1%.

---

**Table 1** Classification of chronic primary headaches

<table>
<thead>
<tr>
<th>Duration</th>
<th>Frequency ≥15 days/month</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long (≥4 hours)</td>
<td>Chronic migraine</td>
</tr>
<tr>
<td></td>
<td>Chronic tension-type headache</td>
</tr>
<tr>
<td></td>
<td>Hemicrania continua</td>
</tr>
<tr>
<td></td>
<td>New daily persistent headache</td>
</tr>
<tr>
<td>Short (&lt;4 hours)</td>
<td>Chronic cluster headache</td>
</tr>
<tr>
<td></td>
<td>Chronic paroxysmal hemicrania</td>
</tr>
</tbody>
</table>

Abbreviation: SUNCT, short-lasting, unilateral, neuralgiform headache attacks with conjunctival injection and tearing.

**Table 2** Diagnostic criteria for chronic migraine according to the ICHD–3 beta

| Criteria A: headache (tension-type-like and/or migraine-like) on ≥15 days per month for > 3 months and fulfilling criteria B and C |
| Criteria B: occurring in a patient who has had at least five attacks fulfilling criteria B–D for 1.1 migraines without aura and/or criteria B and C for 1.2 migraine with aura |
| Criteria C: on ≥8 days per month for > 3 months, fulfilling any of the following three  
  | • Criteria B and C for 1.1 migraine without aura  
  | • Believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative  
  | • Criteria D: not better accounted for by another ICHD–3 diagnosis |

**Criteria B–D for migraine without aura**

| Criteria B: headache attacks lasting 4–72 hours (untreated or unsuccessfully treated)  
  | Criteria C: headache has at least two of the following four characteristics  
  | • Unilateral location  
  | • Pulsating quality  
  | • Moderate or severe pain intensity  
  | • Aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)  
  | Criteria D: during headache at least one of the following  
  | • Nausea and/or vomiting  
  | • Photophobia and phonophobia |

**Criteria B and C for 1.2 migraine with aura**

| Criteria B: one or more of the following fully reversible aura symptoms  
  | • Visual  
  | • Sensory  
  | • Speech and/or language  
  | • Motor  
  | • Brainstem  
  | • Retinal |

| Criteria C: at least two of the following four characteristics  
  | • At least one aura symptom spreads gradually over ≥5 minutes, and/or two or more symptoms occur in succession  
  | • Each individual aura symptom lasts 5–60 minutes  
  | • At least one aura symptom is unilateral  
  | • The aura is accompanied, or followed within 60 minutes, by headache |

Abbreviation: ICHD, International Classification of Headache Disorders.
When less-restrictive diagnostic criteria were used and patients with MOH were included, then the estimated global prevalence of CM ranged between 1%–5%. In the United States, CM prevalence has been estimated at 2.5%; about 3.2 million people may suffer this chronic condition.

Incidence studies are scarce. Episodic migraine (EM) can be considered a progressive disease that may transform to CM at a rate of 2.5%–3% per year. The AMPP study showed that about 2.5% of patients affected by EM progressed yearly to CM, whereas the EM peak usually occurs around the age of 30–35. The highest peak of CM usually happens 10 years later. CM may affect females in approximately 80% of cases. Nevertheless, CM may also affect adolescents in approximately 0.8%–1.8% of cases.

**Disability**

CM has been associated with adverse outcomes including greater headache-related disability, deterioration in health-related quality of life, and increased direct and indirect costs when compared to EM. The AMPP study showed that CM patients significantly had higher (worse) scores in the Migraine Disability Assessment Scale when compared to EM patients (37.9% versus 9.5%, respectively). CM-related disability was also highest among females compared with males.

In a systematic review of 34 studies, chronic daily headache and CM were consistently associated with greater disability and productivity loss, more consultations, more or longer hospitalizations, and higher direct costs than episodic headache. The loss of productive time is more costly and increases more rapidly for people with CM than for those with EM, as age increases.

**Remission**

Studies about the prognosis and natural history of CM are scarce. In a study of nearly 400 CM patients, only 26% had CM remission at 2 years. Remission was defined as fewer than 10 days of headache per month, and reported remission predictors were the absence of allodynia and having a lower baseline headache frequency.

**Pathophysiology of chronic migraine**

Although the source of pain persistence in CM is unknown, it is thought that pain pathways may become sensitized by repeated episodes of trigeminal activation. The chronification of migraine may be a gradual process. An increased frequency of migraine attacks and a genetic susceptibility, linked to risk factors and comorbidities, may favor chronification. In this context, trigeminovascular complex central hypersensitivity could increase excitability and/or reduce pain inhibitory mechanisms.

Trigeminovascular system can be activated during migraine attacks, either changing the modulating nociceptive inputs from the locus coeruleus and raphe nucleus in the brainstem or due to a cortical spreading depression phenomenon. Structural, physiologic, and biochemical alterations can occur in the brain of EM patients. Morphological changes include reduced cortical gray matter in the pain-processing areas of the brain and iron accumulation in the periaqueductal gray matter, red nucleus, and basal ganglia. The brain of CM patients also exhibits metabolic changes and hyperexcitability of the central nervous system and central sensitization. These changes may be more marked compared to EM.

Increased frequency of migraine attacks is associated with changes in the key brainstem areas, basal ganglia, and cortical areas involved in pain perception. A high baseline number of migraine days is associated with CM, and the risk of chronification has been associated with a higher frequency of migraine attacks. Patients who suffer 5–9 days of migraine may have a six-fold more likely chance to develop CM compared to patients with <4 days of headache per month.

Cutaneous allodynia is a marker of central sensitization and an independent predictor for migraine chronification. Cutaneous allodynia is more often seen in CM and is correlated with the duration of migraine illness and the frequency of attacks. Peripheral sensitization (first-order sensitization) occurs during migraine attacks; trigeminal nerves and blood vessels are sensitized and result in throbbing pain that is aggravated by physical activities. Second-order neuron sensitization occurs when sensitization spreads to trigeminovascular neurons in the spinal trigeminal nucleus and cause scalp hypersensitivity or cutaneous allodynia. Finally, third-order neuron sensitization occurs when sensitization spreads to the thalamus, provoking allodynia of the trunk and limbs.
Diagnosis relies on the ICHD–3 beta criteria, as no biomarkers are available for CM.\(^1\) Intercellular calcitonin gene-related peptide (CGRP) levels in peripheral blood may be a potential biomarker for permanent trigemino-vascular activation in CM. In a recent study, CGRP levels were measured in 103 CM women, 31 matched healthy women, and 43 matched women affected by EM. Intercellular CGRP levels were significantly increased in CM patients (74.9 pg/mL) compared with healthy women (33.7 pg/mL) and EM patients (46.4 pg/mL).\(^{26}\)

### Risk factors and comorbidity

#### Risk factors

Epidemiological studies have identified several risk factors associated with CM; these are summarized in Table 3. Modifiable risk factors include: migraine progression (defined as an increase in frequency and severity of migraine attacks); medication overuse; obesity; depression; stressful life events; and snoring among others.\(^{12,27}\) Lifetime depression may be an independent risk factor for allodynia.\(^{25}\) The ICHD–3 suggests that the most common cause of symptoms suggestive of CM is medication overuse. Right-to-left shunt prevalence in CM may be similar to that found in EM, so patent foramen ovale is unlikely to have any significant role in CM.\(^{28}\)

Obesity defined as body mass index (BMI) >30 kg/m\(^2\) has been associated with an increased risk of CM.\(^{29}\) Obesity has also been linked to sleep apnea, snoring, and insulin resistance status in CM.\(^{29,30}\) BMI may have a strong influence on the CM prevalence. Overweight (BMI, 25–29.9), obesity (BMI, 30–34.9), and morbid obesity (BMI, >35) have been associated with an increased risk of CM. The odds ratio is 1.4, 1.7, and 2.2, respectively.\(^{30}\)

#### Table 3 Risk factors for chronic migraine

<table>
<thead>
<tr>
<th>Sociodemographic factors</th>
<th>Modifiable risk factors</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex</td>
<td>High frequency of attacks (episodic migraine)</td>
<td></td>
</tr>
<tr>
<td>Older age</td>
<td>Anxiety and depression</td>
<td></td>
</tr>
<tr>
<td>Low educational level</td>
<td>Stressful life events</td>
<td></td>
</tr>
<tr>
<td>Low income</td>
<td>Obesity</td>
<td></td>
</tr>
<tr>
<td>Genetic factors</td>
<td>Heavy caffeine consumption</td>
<td></td>
</tr>
<tr>
<td>Caucasian ethnicity</td>
<td>Tobacco use</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Overuse of abortive headache medication</td>
<td></td>
</tr>
</tbody>
</table>

The proportion of CM patients that uses preventive medication is low. Only approximately one-third of CM patients may be taking adequate preventive medication. The absence of adequate preventive medication can favor the increase of migraine attacks. Population and cross-cultural studies have shown significant differences in the rate of migraine prevention.\(^{31}\) The second International Burden of Migraine Study (IBMS-II) showed that < one-half of CM patients were currently using any preventive medication.\(^{32}\)

The use of prior preventive medication was reported in 66%, and the mean number of prophylactic medications ever used was 3.9.

#### Medication overuse

Many patients with CM also report some degree of medication overuse, but it is difficult to determine whether the chronic use of painkillers is the cause or the consequence of CM. Overuse has been defined as 10 days or more of intake of triptans, ergot alkaloids, mixed analgesics or opioids, and 15 days or more of analgesics/nonsteroid anti-inflammatory drugs, or the combined use of more than one substance.\(^1\)

Combination of analgesics – such as butalbital/acetaminophen/caffeine – has been frequently associated with MOH; whereas, nonsteroidal anti-inflammatory drugs have less potential to cause MOH. Triptans may also have the potential to cause MOH. Opioids and barbiturate combination overuse and high caffeine consumption are also risk factors for CM transformation. The AMPP study showed that chronification was most likely to occur with 5 days of butalbital use per month, 8 days of opioid use per month, 10 days of triptan or combination analgesic per month, and 10–15 days of nonsteroidal anti-inflammatory use per month.\(^{33}\)

According to ICHD–3 beta, approximately 50% of patients diagnosed with CM may revert to EM subtype after drug withdrawal. Many headache specialists think that these patients are in a sense wrongly diagnosed as CM. In addition, many patients who overuse medication do not improve after drug withdrawal, and the diagnosis of MOH would be inappropriate. For these reasons, the ICHD–3 beta recommends that for patients who meet the criteria for 1.3 chronic migraine and for 8.2 medication-overuse headache that both diagnoses should be given.\(^1\)

#### Comorbidity

Migraine has been associated with some comorbid conditions. Chronic pain at other locations, mood disorders, some respiratory conditions, and vascular risk factors have all been
reported in a significantly higher frequency in CM compared to EM. In the AMPP study, CM patients were approximately twice as likely to have depression, anxiety, and chronic pain. Respiratory disorders including asthma, bronchitis and chronic obstructive pulmonary disease, and cardiac risk factors, such as hypertension, diabetes, high cholesterol, and obesity, were reported to be significantly more common in CM. The odds ratio ranged from 1.43 (cardiopathy) to 1.99 (bronchitis) (Table 4).27

Management of chronic migraine
CM management is a complex issue that should include modification of risk factors, treatment of associated comorbidities, identification of medication overuse, treatment of acute migraine attacks, and preventive therapy.7 Adequate preventive medication use for those patients suffering EM should be started when progression occurs to prevent CM.

Early diagnosis of CM and the detection and identification of risk factors for chronification are essential. Training of primary care physicians and neurologists is needed as diagnostic criteria for CM have not yet been unanimously accepted in the past. Once CM is identified, physicians should be aware of the difficulties of treating CM. If medication overuse is identified, the withdrawal of analgesics, opioids, and caffeine should be advised.

Optimizing mood, reducing stress, practicing good sleep hygiene, and avoiding triggers are recommended to treat CM. Strategies should be started to treat risk factors and comorbid conditions including obesity, depression, high blood pressure, neck chronic pain, and sleep and mood disorders. Keeping a headache diary or calendar would give us clinical information regarding triggers, patterns of MOH, and the frequency of headache attacks.14 The role of migraine nurse specialists and psychologists should be integrated into preventive programs.

Preventive medication
Preventive medication for CM includes antiepileptic drugs (topiramate, sodium valproate), antidepressants (amitriptyline), and onabotulinumtoxinA (155–195 units). Treatment should be started with topiramate, perhaps the drug with the highest evidence to treat CM. OnabotulinumtoxinA could be considered when at least two consecutive trials of other preventive drugs have failed. Compliance needs to be assessed, as many CM patients may fail to take preventive medication. Observational studies and pooled data from randomized trials have demonstrated poor adherence to migraine prophylaxis.35

Antiepileptic/antidepressants drugs
Several double-blind, randomized, placebo-controlled clinical trials showed that topiramate may cause a significant reduction of migraine days in CM patients. In the European Topiramate in Chronic Migraine (TOPCHROME) study, 32 patients received topiramate (mean dose, 100 mg/day), and 27 patients received a placebo. Topiramate significantly reduced the mean number of monthly migraine days by 3.5 compared with the placebo, and 22% of CM patients had a 50% or greater reduction in the mean number of headache days per month.36 In the US, a randomized clinical trial that included 306 CM patients evaluated the efficacy of topiramate in CM. Patients received a dose of 100 mg per day, and a decrease in mean monthly headache days was observed (5.8 days for topiramate versus 4.7 for placebo treatment).37 Both studies demonstrated the efficacy and safety of topiramate as preventive medication for CM patients with and without medication overuse. The post hoc analysis of CM patients with overuse medication concluded that detoxification prior to initiating prophylactic therapy may not be required if medication overuse is present.38

The efficacy of sodium valproate was evaluated in a small group of 29 CM patients and 41 chronic tension-type headache patients. Patients were randomized to 500 mg twice a day or placebo for 3 months, and a significant improvement in the severity and frequency of pain was reported in the CM subgroup.39 Other randomized clinical trials have assessed the efficacy of tizanidine (titrated to target dose of 24 mg) and gabapentin (titrated to 2,400 mg daily) in CM and a significantly lower rate of headache days as compared to placebo were found.40,41

Table 4 Comorbidities associated with chronic migraine

<table>
<thead>
<tr>
<th>Condition</th>
<th>CM, %</th>
<th>EM, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthritis</td>
<td>33.6</td>
<td>22.2</td>
</tr>
<tr>
<td>Chronic pain</td>
<td>31.5</td>
<td>15.1</td>
</tr>
<tr>
<td>Anxiety</td>
<td>30.2</td>
<td>18.8</td>
</tr>
<tr>
<td>Depression</td>
<td>30.2</td>
<td>17.2</td>
</tr>
<tr>
<td>Obesity</td>
<td>25.5</td>
<td>21.0</td>
</tr>
<tr>
<td>Heart disease</td>
<td>9.6</td>
<td>6.3</td>
</tr>
<tr>
<td>HTA</td>
<td>33.7</td>
<td>27.8</td>
</tr>
<tr>
<td>Asthma</td>
<td>24.4</td>
<td>17.2</td>
</tr>
<tr>
<td>Bronchitis</td>
<td>9.2</td>
<td>4.5</td>
</tr>
<tr>
<td>COPD</td>
<td>4.9</td>
<td>2.6</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>45.2</td>
<td>37.0</td>
</tr>
</tbody>
</table>

Note: Data from Buse et al.27
Abbreviations: CM, chronic migraine; EM, episodic migraine; HTA, hypertension; COPD, chronic obstructive pulmonary disease.

COPD, chronic obstructive pulmonary disease.
The Amitriptyline Versus Placebo Study Group published a reanalysis of a clinical trial that included 391 subjects. For the subgroup with chronic daily headache, amitriptyline titrated to 100 mg daily was significantly superior to placebo at 8 weeks and at 16 weeks. In addition, there was a trend for amitriptyline to be superior to placebo at 12 weeks and at 20 weeks, but this did not reach significance.\(^\text{42}\)

**OnabotulinumtoxinA**

Botulinum toxin is a neurotoxin produced by anaerobic bacterium *Clostridium botulinum* that can improve several painful conditions including migraine. Although its antinociceptive mechanisms have not been clearly understood, onabotulinumtoxinA inhibits the release of nociceptive mediators such as substance P, CGRP, and glutamate from the peripheral terminals of primary afferents. The two Phase III REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical trials showed that onabotulinumtoxinA is a safe, well-tolerated, and effective prophylactic therapy for CM patients.\(^\text{43-45}\)

The protocol of the PREEMPT study required the injection of 150 units of onabotulinumtoxinA in 31 fixed sites at a fixed-dose of five units in each muscle. The injected muscles included procerus, bilateral corrugators, frontalis, temporalis, occipitais, cervical, paraspinal, and superior trapezius muscles.\(^\text{46}\)

A total of 1,384 patients were randomized to onabotulinumtoxinA (n=688) or placebo (n=696) in the double-blind phase of PREEMPT trials. At 24 weeks, around 47% of onabotulinumtoxinA-treated patients had a decrease in the frequency of headache days higher than 50% compared with 35% of placebo-treated patients. A pooled analysis showed that onabotulinumtoxinA treatment significantly reduced headache-day frequency versus placebo in patients with CM at week 56. A significant reduction in the frequency of migraine days and cumulative headache hours on headache days was also observed.\(^\text{47}\)

The 62.4% of onabotulinumtoxin A-treated patients and the 51.7% of placebo-treated patients reported an adverse event. Most adverse events were mild to moderate in severity, and only 3.8% of onabotulinumtoxinA-treated patients (and 1.2% of placebo-treated patients) discontinued therapy due to adverse events.\(^\text{48}\) OnabotulinumtoxinA is an expensive preventive treatment for CM. However, cost could be reduced by less triptan use for the acute migraine attacks.\(^\text{49}\) A cost-effectiveness analysis showed that onabotulinumtoxinA reduced headache days by an estimated 38 days per year at a cost of £18 per headache avoided in adults with CM in United Kingdom.\(^\text{50}\)

A few studies have compared topiramate and onabotulinumtoxinA in CM prevention and found similar efficacy. In a study of 60 CM patients who were randomized to 200 units of onabotulinumtoxinA versus topiramate 200 mg daily, a reduction >50% in the mean number of headache days were observed in 41% of onabotulinumtoxinA-treated patients and 43% of topiramate-treated ones.\(^\text{51}\) The second study recruited a small sample of 59 subjects that were randomized to topiramate (200 mg daily) or onabotulinumtoxinA (200 units). At week 12, a decrease in the mean number of headache days per month was similar in both groups (12.4 versus 13.8 days).\(^\text{52}\)

**Open studies and combination therapies in CM**

The results of several open-label trials have been published and they suggest some degree of efficacy for zonisamide (400 mg daily),\(^\text{53,54}\) pregabalin (150 mg twice-a-day),\(^\text{55}\) flunarizine (10 mg daily),\(^\text{56}\) atenolol (50 mg daily),\(^\text{57}\) and memantine (10–20 mg daily),\(^\text{58}\) to treat CM. However, more evidence and further randomized clinical trials are needed to demonstrate their efficacy in CM.

There are only a few studies that have evaluated the efficacy of combination therapies in CM. A randomized, placebo-controlled trial of propranolol added to topiramate in CM has been published.\(^\text{59}\) The result of this study showed that the addition of propranolol long-acting (240 mg daily) to topiramate 50–100 mg per day does not add benefit when CM is inadequately controlled with topiramate alone. In another small pilot trial of 28 subjects, the combination of sumatriptan 85 mg plus naproxen 500 mg in a combination tablet did not reduce headache frequency over a 3-month period.\(^\text{60}\) Nevertheless, further clinical trials are needed to search for better combination therapies for CM patients.

An unresolved question is whether migraine patients with medication overuse should taper off the overused medication before starting any preventive medication. The post hoc analysis of the European and US topiramate clinical trials and the results of onabotulinumtoxinA trials suggest some type of benefit for patients overusing triptans and other medications.\(^\text{38,45}\)

**Cognitive-behavioral therapy and other therapies**

Several studies have assessed the role of complementary and alternative therapies in CM. Biobehavioral techniques used in chronic headache include relaxation training, thermal biofeedback, electromyography biofeedback, and cognitive-behavioral therapy.
Although biofeedback, relaxation technique, and cognitive-behavioral therapies have demonstrated efficacy in the prevention of EM, data regarding efficacy in CM are limited. Behaviorial sleep modification proved to be effective for transformed migraine.

Relaxation training and biofeedback are directed toward the sensory component that involves the perception of physical sensations including pain. Biofeedback training targets those physical responses that are believed to contribute to increase the susceptibility and maintenance of chronic headache. Cognitive and behavioral strategies focus on the reactive component of the pain experience.

The rationale of cognitive-behavioral therapies in CM is that chronic headache should be recognized and thoroughly examined by the patient to be successfully managed. Being aware of factors that precipitate or aggravate CM should allow patients to progressively modulate the frequency and duration of their attacks. Cognitive-behavioral therapy may also be indicated to assess compliance to preventive medication and to assess modifiable risk factors for CM. Other reasons that cause CM patients to seek cognitive-behavioral therapy and other nonpharmacological treatments include poor tolerance and low response to preventive medication, history of overuse of medication, pregnancy, stress, and deficient stress/pain coping strategies.

The goals of cognitive-behavioral therapy in CM are summarized in Table 5. CM patients are taught self-regulation techniques and cognitive and behavioral coping skills. Diaries and headache calendars may be helpful to adequately register the patient’s treatment progress. CM patients are also encouraged to modify risk factors to reduce frequency and severity of headache.

Cognitive-behavioral therapy can be helpful as part of a combined treatment, and it should be integrated with pharmacological interventions, physical, and aerobic training. A randomized clinical trial evaluated the efficacy of cognitive-behavioral therapy plus amitriptyline in CM children and adolescents aged 10–17 years. Also, 135 youth patients (79% female) diagnosed with CM were recruited and randomized to the cognitive-behavioral therapy plus amitriptyline group (n=64) or the headache education plus amitriptyline group (n=71). A greater reduction in headache days and migraine-related disability was observed in the cognitive-behavioral therapy plus amitriptyline group, as compared to headache education/amitriptyline group.

Acupuncture may be beneficial when added to medical treatment. A randomized clinical trial of 66 patients evaluated the efficacy of acupuncture administered in 24 sessions over 12 weeks versus topiramate (100 mg daily) in CM. Although this was a nonblind study, researchers found a significant decrease in the mean number of headache days in the acupuncture branch as compared to the topiramate.

**Occipital nerve stimulation**

Occipital nerve stimulation has been assessed in patients with refractory CM. Three randomized sham-controlled trials have evaluated the efficacy of occipital nerve stimulation in CM at 12 weeks, and the overall results have been considered disappointing. In the Precision Implantable Stimulator for Migraine (PRISM) trial, 125 refractory CM patients were treated with occipital nerve stimulation or sham, and no significant improvement was observed.

The Occipital Nerve Stimulation for the Treatment of Intractable Migraine (ONSTIM) study assessed the efficacy of occipital nerve stimulation in 75 CM patients. After 3 months, a 50% reduction in headache was reported in 39% of patients who had adjustable stimulation and in 5% who had preset stimulation. However, lead migration occurred in 24% of subjects.

A recent large-scale randomized controlled multicenter study of CM patients showed that there was not a significant difference in the percentage of responders in the active compared with the control group at 12 weeks. Active group patients (n=105) were implanted with a neurostimulation device near the occipital nerve; whereas, 52 patients received sham stimulation. Compared with the sham-treated group, significant differences in the reduction of number of headache days, migraine-related disability, and direct reports of pain were observed in the active group.

Another study of 30 patients reported that headache intensity and frequency were significantly lower in the “on” arm as compared to the “off” one. Dual occipital and supraorbital nerve stimulation have also been evaluated in a small study of 14 patients, and approximately 70% of them had a 50% or greater decrease in pain severity.
Occipital nerve stimulation is a relatively safe technique although invasive and expensive, and this factor may also limit its use in clinical practice. Adverse effects have been reported and include lead migration, local acute or delayed infections, and battery depletion due to the high stimulation intensity needed in some patients. Occipital nerve stimulation can also induce paresthesias covering the great occipital nerve territory.

The position statement from the European Headache Federation concludes that the application of neurostimulation for CM should be considered only after all alternative drugs and behavioral therapies, as recommended by international guidelines, have failed, and medication overuse headache excluded. The use of occipital nerve stimulation seems acceptable in CM, although it is based on limited evidence.

The effect of infiltrations on the occipital nerve in CM is unknown. An open-label study assessed the efficacy and safety of the occipital nerve block in 150 patients affected with CM and associated cervicogenic triggers. Thirty-seven CM patients were treated with unilateral occipital nerve block; 113 received bilateral occipital nerve blocks. Also, one-half of the patients had a 50% reduction in headache days over the month following the occipital nerve block. However, 5% of patients reported adverse events within the ensuing 72 hours.

**Conclusion**

Diagnosis, treatment, and prevention for CM are challenging. Educational programs should be proposed for EM patients as they should be warned about the potential risk of chronicification of the disease. Early detection and management of modifiable risk factors, such as migraine progression, medication overuse, obesity, depression, and stressful life events, are also important to avoid the chronicification of migraine. Preventive medication may be ineffective in many patients; some frequently report side effects of medication. Many of these may also suffer from MOH and even a subgroup of patients may suffer “intractable” or refractory CM. The amount of randomized clinical trials in CM is limited, and the number of recruited patients has been small. Different diagnostic criteria and outcomes have been used and this fact may limit comparison and generalization of their results.

**Disclosure**

The author reports no conflicts of interest in this work.

**References**


